Journal of International Medical Research (Jun 2020)

Clinical features related to hospital expenses for non-cystic fibrosis bronchiectasis in China

  • Yanliang Ma,
  • Daishun Liu,
  • Yingqun Ji,
  • Xuemei Wei,
  • Dianzhu Pan,
  • Fei Xu,
  • Qingguo Di,
  • Xiaoju Chen,
  • Fengming Luo,
  • Jiujin Zhang,
  • Guiying Ou,
  • Yan Zhang,
  • Kaishu Li,
  • Dong Zhang,
  • Wanping Wang,
  • Jinfu Xu,
  • Jianying Li,
  • Dan Zhu,
  • Feng Tian,
  • Manqi Fan

DOI
https://doi.org/10.1177/0300060520932116
Journal volume & issue
Vol. 48

Abstract

Read online

Objective Bronchiectasis is a common chronic airway disease. We investigated the economic burden and associated factors of bronchiectasis in China. Methods In this multicenter retrospective cohort study, we reviewed medical records of patients admitted to 18 tertiary hospitals during 2010 to 2014 with a bronchiectasis-related diagnosis. Results A total 5469 patients with bronchiectasis were admitted, accounting for 3.13% ± 1.80% of all discharged patients with any diagnosis during the same period; 13 patients died upon discharge. The median hospitalization cost was RMB 8421.52 (RMB 5849.88–12,294.47). Risk factors associated with hospitalization costs included age at admission (>70 vs. 80 vs. 15 packs/year vs. non-smokers, OR = 1.127, 95% CI = 1.062–1.228), length of hospitalization (OR = 1.05, 95% CI = 1.046–1.054), combination antibiotic treatment (OR = 1.089, 95% CI = 1.033–1.148), cough (OR = 0.851, 95% CI = 0.751–0.965), dyspnea (OR = 0.93, 95% CI = 0.878–0.984), chronic obstructive pulmonary disease (OR = 0.935, 95% CI = 0.878–0.996), respiratory failure (OR = 0.923, 95% CI = 0.862–0.989), cor pulmonale (OR = 0.919, 95% CI = 0.859–0.982), and death (OR = 1.816, 95% CI = 1.113–2.838). Conclusions Age, smoking status, symptoms, and respiratory comorbidities were associated with hospitalization costs of bronchiectasis.